Retapamulin: what is the role of this topical antimicrobial in the treatment of bacterial infections in atopic dermatitis?
暂无分享,去创建一个
[1] S. Sicherer. Treatment of Staphylococcus aureus Colonization in Atopic Dermatitis Decreases Disease Severity , 2009, Pediatrics.
[2] P. Schalock. Allergic contact cermatitis to retapamulin ointment , 2009, Contact dermatitis.
[3] N. Katoh. Future perspectives in the treatment of atopic dermatitis , 2009, The Journal of dermatology.
[4] D. Hoban,et al. Microbiological profile of a new topical antibacterial: retapamulin ointment 1% , 2009, Expert review of anti-infective therapy.
[5] N. Novak. New insights into the mechanism and management of allergic diseases: atopic dermatitis , 2009, Allergy.
[6] A. Kedzierska,et al. Susceptibility testing and resistance phenotype detection in Staphylococcus aureus strains isolated from patients with atopic dermatitis, with apparent and recurrent skin colonization , 2008, The British journal of dermatology.
[7] N. Woodford,et al. In vitro activity of retapamulin against Staphylococcus aureus isolates resistant to fusidic acid and mupirocin. , 2008, The Journal of antimicrobial chemotherapy.
[8] H. Williams,et al. Interventions to reduce Staphylococcus aureus in the management of atopic eczema. , 2008, The Cochrane database of systematic reviews.
[9] O. Chosidow,et al. Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double‐blind multicentre placebo‐controlled trial , 2008, The British journal of dermatology.
[10] O. Chosidow,et al. Topical Retapamulin Ointment, 1%, versus Sodium Fusidate Ointment, 2%, for Impetigo: A Randomized, Observer-Blinded, Noninferiority Study , 2007, Dermatology.
[11] B. Chiang,et al. Role of Bacterial Pathogens in Atopic Dermatitis , 2007, Clinical reviews in allergy & immunology.
[12] Marta Hasse-Cieślińska. Staphylococcus aureus skin colonization in atopic dermatitis patients , 2007 .
[13] W. S. Champney,et al. Retapamulin Inhibition of Translation and 50S Ribosomal Subunit Formation in Staphylococcus aureus Cells , 2007, Antimicrobial Agents and Chemotherapy.
[14] D. Holmes,et al. Stepwise Exposure of Staphylococcus aureus to Pleuromutilins Is Associated with Stepwise Acquisition of Mutations in rplC and Minimally Affects Susceptibility to Retapamulin , 2007, Antimicrobial Agents and Chemotherapy.
[15] L. Dubreuil,et al. In vitro activity against anaerobes of retapamulin, a new topical antibiotic for treatment of skin infections. , 2007, The Journal of antimicrobial chemotherapy.
[16] J. Jorizzo,et al. Topical retapamulin ointment (1%, wt/wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: results of a randomized controlled trial. , 2006, Journal of the American Academy of Dermatology.
[17] D. Payne,et al. Selection of Retapamulin, a Novel Pleuromutilin for Topical Use , 2006, Antimicrobial Agents and Chemotherapy.
[18] Scott White,et al. Retapamulin ointment twice daily for 5 days vs oral cephalexin twice daily for 10 days for empiric treatment of secondarily infected traumatic lesions of the skin. , 2006, Skinmed.
[19] R. Copeland,et al. Biochemical Characterization of the Interactions of the Novel Pleuromutilin Derivative Retapamulin with Bacterial Ribosomes , 2006, Antimicrobial Agents and Chemotherapy.
[20] Ronald N. Jones,et al. Activity of Retapamulin (SB-275833), a Novel Pleuromutilin, against Selected Resistant Gram-Positive Cocci , 2006, Antimicrobial Agents and Chemotherapy.
[21] B. Zhao,et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double‐blind multicentre randomized controlled trial , 2006, The British journal of dermatology.
[22] T. Biedermann. Dissecting the role of infections in atopic dermatitis. , 2006, Acta dermato-venereologica.
[23] M. Jacobs,et al. Activity of Retapamulin against Streptococcus pyogenes and Staphylococcus aureus Evaluated by Agar Dilution, Microdilution, E-Test, and Disk Diffusion Methodologies , 2006, Antimicrobial Agents and Chemotherapy.
[24] P. Mcghee,et al. Single- and Multistep Resistance Selection Studies on the Activity of Retapamulin Compared to Other Agents against Staphylococcus aureus and Streptococcus pyogenes , 2006, Antimicrobial Agents and Chemotherapy.
[25] A. Finlay,et al. Staphylococcus aureus re‐colonization in atopic dermatitis: beyond the skin , 2005, Clinical and experimental dermatology.
[26] S. Häussler,et al. Staphylococcus aureus: colonizing features and influence of an antibacterial treatment in adults with atopic dermatitis , 2002, The British journal of dermatology.
[27] Ewing,et al. Flucloxacillin in the treatment of atopic dermatitis , 1998, The British journal of dermatology.
[28] N. Ganguly,et al. Role of bacterial flora in the pathogenesis & management of atopic dermatitis. , 1992, The Indian journal of medical research.
[29] J. Leyden,et al. The case for steroid—antibiotic combinations , 1977, The British journal of dermatology.
[30] M. Komine. Analysis of the mechanism for the development of allergic skin inflammation and the application for its treatment:keratinocytes in atopic dermatitis - their pathogenic involvement. , 2009, Journal of pharmacological sciences.
[31] S. Keam,et al. Retapamulin , 2012, Drugs.
[32] S. Keam,et al. Spotlight on Retapamulin in Impetigo and Other Uncomplicated Superficial Skin Infections† , 2008, American journal of clinical dermatology.
[33] 有川 順子. Decreased levels of sphingosine, a natural antimicrobial agent, may be associated with vulnerability of the stratum corneum from patients with atopic dermatitis to colonization by Staphylococcus aureus , 2003 .
[34] K. Thomsen,et al. Fusidic acid plus betamethasone in infected or potentially infected eczema. , 1985, Pharmatherapeutica.